Thus, the coexistence of a somatic BRAF mutation and tumor dMMR/MSI-H status not only suggests a sporadic origin but may also be a marker for prognostic risk stratification in metastatic CRC, as BRAF-mutated tumors exhibiting MSI-H have been associated with poorer survival in the metastatic setting [63,64,65]. This evidence concerns the gene BRAF and neoplasm.